-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
-
Summary
-
Ultragenyx Pharmaceutical Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2012 to 2023.
- Ultragenyx Pharmaceutical Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$134M, a 16.4% increase year-over-year.
- Ultragenyx Pharmaceutical Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$559M, a 12% increase year-over-year.
- Ultragenyx Pharmaceutical Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$607M, a 14.2% increase from 2022.
- Ultragenyx Pharmaceutical Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$707M, a 55.8% decline from 2021.
- Ultragenyx Pharmaceutical Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$454M, a 143% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)